More from Renaissance Capital
Referenced Stocks

KYTHERA Biopharma prices upsized deal at $16, at high end of the range

By Renaissance Capital,  October 11, 2012, 08:36:12 AM EDT

KYTHERA Biopharmaceuticals, which is commercializing an injectable treatment for double chins with Bayer, raised $70 million by offering 4.4 million shares at $16, at high end of the range of $14 to $16. The 4.4 million shares offered was 10% more than originally anticipated. KYTHERA Biopharma plans to list on the NASDAQ under the symbol KYTH. J.P. Morgan and Goldman Sachs acted as lead managers on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.


This article appears in: News Headlines, IPOs

Referenced Stocks: KYTH



Latest News Video

Obama's Approval Rating Remains Steady
Obama's Approval Rating Remains Ste...
Princes Open Help For Heroes Centre
Princes Open Help For Heroes Centre
'Crazy Ants' Displacing Fire Ants in U.S.
'Crazy Ants' Displacing Fire Ants i...
Powerful Tornadoes Strike Oklahoma
Powerful Tornadoes Strike Oklahoma  


Sign-in
Existing NASDAQ.com member? Log in here.

By signing into to the site using any of the third-party services above, you agree to NASDAQ.com's Terms of Use.

From Our Trusted News Source





Most Active by Volume:

Company Last Sale Change Net / %
BAC $ 13.529 0.10  0.74%
RAD $ 2.95 0.16  5.73%
WCRX $ 19.78 0.57  2.97%
CSCO $ 23.66 0.58  2.39%
SIRI $ 3.51 0.01  0.29%
FB $ 25.8285 0.42  1.61%
MSFT $ 34.85 0.02  0.06%
ELN $ 12.05 0.38  3.26%